Financial Report: Teva

Teva

3Q Revenues: $5.1 billion (+2%)

3Q Earnings: $706 million (loss of $84 million 3Q12)

YTD Revenues: $14.9 billion (-1%)

YTD Earnings: $876 million (-46%)

Comments: Generic revenues were flat in the quarter at $2.5 billion (including API sales of $162 million). U.S. revenues were $1.1 billion, up 6%. European revenues were $812 million, down 1%. ROW revenues were $533 million, down 11%, primarily due to foreign currency effects. Specialty medicines revenues were $2.1 billion, up 3%, primarily due to increased revenues of women’s health, oncology and respiratory medicines, as well as Azilect (+21% to $93 million), partially offset by lower revenues of Provigil (-58% to $22 million) and Nuvigil (-7% to $87 million). U.S. revenues were $1.5 billion, up 3%, European revenues of $426 million, up 12%. ROW revenues were $144 million, down 17%. OTC revenues were $286 million, up 13%, primarily due to higher sales of PGT Healthcare portfolio medicines.